Sign in

    Caroline Palomeque

    Senior Vice President and Senior Biotechnology Analyst at Maxim Group

    Caroline Palomeque is a Senior Vice President and Senior Biotechnology Analyst at Maxim Group, specializing in equity research across the healthcare and biotechnology sectors. She covers specific companies including SELLAS Life Sciences Group, Immutep Limited, Daré Bioscience, Harmony Biosciences Holdings, Krystal Biotech, Halozyme Therapeutics, Ascendis Pharma, Denali Therapeutics, REGENXBIO, and Anavex Life Sciences, maintaining a success rate of 55.56% and an average analyst return of 16.24%. Palomeque began her analyst career at Noble Life Science Partners and WallachBeth Capital before joining Maxim Group in 2018, and she also has research experience in molecular epidemiology at Mount Sinai. She holds professional credentials in equity research and has coauthored peer-reviewed scientific publications, with her work being recognized and utilized in investment banking contexts.

    Caroline Palomeque's questions to SELLAS Life Sciences Group (SLS) leadership

    Caroline Palomeque's questions to SELLAS Life Sciences Group (SLS) leadership • Q3 2018

    Question

    Caroline Palomeque of Maxim Group asked about the expected trends in operating expenses for the upcoming year, given the initiation of new clinical trials in the first quarter.

    Answer

    CFO Gene Mack responded that the company has control over its cash burn and reiterated previous guidance that current cash and equivalents are sufficient to fund operations through at least March 2019. He stated that an update to this financial guidance would be provided during the fourth-quarter report early next year.

    Ask Fintool Equity Research AI